{"doi":"10.1002/ajh.27630","title":"Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐<scp>GemOx</scp>: A Multicenter Cohort Study","abstract":"Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but there are limited real-world data. In a multicenter retrospective study from a cohort of eight US academic centers (LEO CReWE), we evaluated 183 patients with R/R DLBCL and high-grade B cell lymphoma treated with R-GemOx, including subgroups treated without intent for consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T cell therapy (n = 100), those utilizing R-GemOx as a bridge to ASCT or CAR T (n = 83), and those aged 70 and older (n = 71). Overall response rates (ORRs) for all patients treated with R-GemOx were 45% with a complete response (CR) rate of 29%. The median event-free survival (EFS) was 2.3 months, and the median overall survival (OS) was 13.5 months. Patients receiving R-GemOx without intent for ASCT or CAR T had ORR and CR rates of 33% and 18%, respectively, with median EFS and OS of 2.0 and 9.5 months, respectively. Patients receiving R-GemOx as a bridge to ASCT or CAR T had ORR and CR rates of 57% and 36%, respectively, with median EFS and OS of 3.5 and 17.4 months, respectively. Patients receiving R-GemOx aged 70 and older had ORR and CR rates of 53% and 33%, respectively, with median EFS and OS of 2.2 and 13.9 months, respectively. These data provide a benchmark for R-GemOx in the rapidly evolving landscape of R/R DLBCL therapies.","journal":"American Journal of Hematology","year":2025,"id":516077,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9529,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":680215,"name":"Jean L. Koff","orcid":"0000-0003-4414-0489","position":1,"is_corresponding":false},{"id":33562,"name":"Melissa C. Larson","orcid":"0000-0002-5430-8161","position":2,"is_corresponding":false},{"id":258333,"name":"Brad S. Kahl","orcid":"0000-0003-0459-6609","position":3,"is_corresponding":false},{"id":105212,"name":"Carla Casulo","orcid":"0000-0003-4998-9932","position":4,"is_corresponding":false},{"id":35668,"name":"Izidore S. Lossos","orcid":"0000-0002-9346-9013","position":5,"is_corresponding":false},{"id":1380952,"name":"Sara Haddadi","orcid":"0009-0000-4909-3541","position":6,"is_corresponding":false},{"id":309197,"name":"Michele Stanchina","orcid":"0000-0002-4691-7645","position":7,"is_corresponding":false},{"id":703100,"name":"Dai Chihara","orcid":"0000-0002-1153-2294","position":8,"is_corresponding":false},{"id":638747,"name":"Amy Ayers","orcid":"0000-0003-4807-2356","position":9,"is_corresponding":false},{"id":396925,"name":"Thomas M. Habermann","orcid":"0000-0003-3532-9132","position":10,"is_corresponding":false},{"id":685093,"name":"Yucai Wang","orcid":"0000-0002-1576-8341","position":11,"is_corresponding":false},{"id":1032184,"name":"Arushi Khurana","orcid":"0000-0001-5645-0949","position":12,"is_corresponding":false},{"id":371973,"name":"Grzegorz S. Nowakowski","orcid":"0000-0002-6955-9393","position":13,"is_corresponding":false},{"id":1212946,"name":"Tanner W. Reicks","orcid":null,"position":14,"is_corresponding":false},{"id":11114,"name":"Umar Farooq","orcid":"0000-0001-7891-9891","position":15,"is_corresponding":false},{"id":258325,"name":"Brian K. Link","orcid":"0000-0001-5084-0698","position":16,"is_corresponding":false},{"id":262217,"name":"Jonathon B. Cohen","orcid":"0000-0002-2723-6481","position":17,"is_corresponding":false},{"id":574842,"name":"Peter Martin","orcid":"0000-0001-7813-1551","position":18,"is_corresponding":false},{"id":1333269,"name":"Jia Li","orcid":"0009-0000-6922-3163","position":19,"is_corresponding":false},{"id":858532,"name":"Ashwini Shewade","orcid":null,"position":20,"is_corresponding":false},{"id":237602,"name":"Connie Lee Batlevi","orcid":"0000-0002-9036-9463","position":21,"is_corresponding":false},{"id":1381428,"name":"Andrea Lo‐Rossi","orcid":null,"position":22,"is_corresponding":false},{"id":1380953,"name":"David Fox","orcid":"0000-0002-5465-1648","position":23,"is_corresponding":false},{"id":858531,"name":"Anthony Masaquel","orcid":null,"position":24,"is_corresponding":false},{"id":858530,"name":"Yong Mun","orcid":null,"position":25,"is_corresponding":false},{"id":302818,"name":"James R. Cerhan","orcid":"0000-0002-7482-178X","position":26,"is_corresponding":false},{"id":107379,"name":"Christopher R. Flowers","orcid":"0000-0002-9524-3990","position":27,"is_corresponding":false},{"id":239734,"name":"Matthew J. Maurer","orcid":"0000-0002-1867-0526","position":28,"is_corresponding":false},{"id":98138,"name":"Loretta J. Nastoupil","orcid":"0000-0001-6071-8610","position":29,"is_corresponding":false},{"id":1204301,"name":"Samuel Yamshon","orcid":"0000-0002-4616-8568","position":0,"is_corresponding":true}],"reference_count":22,"raw_metadata":null,"created_at":"2026-07-19T02:48:44.647022Z","pmid":"39918101","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}